Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

A synthetic biology approach for the production of rare cannabinoids with anti-diabetic properties in yeast

EF 2022-23

Résumé
Phytocannabinoids are a group the compounds found in cannabis plants, such as Cannabis sativa, which are recognized to exert various pharmacological activities on different systems. Aside the two major phytocannabinoids ?9-tetrahydrocannabinol (?9-THC) and cannabidiol, those plants also produce other cannabinoids in low levels, called “rare cannabinoids,” which are hypothesized to have pharmacological activity. For example, ?9-tetrahydrocannabivarin (?9-THCV), a phytocannabinoid similar structurally to ?9-THC, potentially exerts anti-obesity and anti-diabetes activity. Currently, phytocannabinoids on the market mostly come from direct extraction of the plants themselves. This method is problematic, because it is highly energy consuming, costly, and only low yields of rare cannabinoids are achieved, limiting bioactivity characterization and clinical use of those compounds as therapeutic agents. An alternative approach for their production is to engineer microbial hosts, such as yeast, to produce them. This offers a low-cost method to produce our compound of interest, ?9-THCV, with high yield. To do this, we will reconstruct pathways known in C. sativa to produce ?9-THCV in yeast and modulate fluxes of native yeast metabolic pathways to redirect metabolic flux towards the engineered ?9-THCV biosynthetic pathway. My proposed approach aims at optimizing the yield of ?9-THCV using artificial intelligence to modify an enzyme important in the process of ?9-THCV production in silico and test it experimentally. This enzyme also needed to produce other rare cannabinoids, this project will enable development of new cannabinoid-based therapies at low cost with strong benefits for the health and wellbeing of worldwide patients and economic impact on the pharmaceutical sector.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486356
Name
Grimard Zachary
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A synthetic biology approach for the production of rare cannabinoids with anti-diabetic properties in yeast
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Artificial Intelligence; Drug Production; Machine Learning; Metabolic Engineering; Molecular Cloning; Synthetic Biology
Abstract
Phytocannabinoids are a group the compounds found in cannabis plants, such as Cannabis sativa, which are recognized to exert various pharmacological activities on different systems. Aside the two major phytocannabinoids ?9-tetrahydrocannabinol (?9-THC) and cannabidiol, those plants also produce other cannabinoids in low levels, called “rare cannabinoids,” which are hypothesized to have pharmacological activity. For example, ?9-tetrahydrocannabivarin (?9-THCV), a phytocannabinoid similar structurally to ?9-THC, potentially exerts anti-obesity and anti-diabetes activity. Currently, phytocannabinoids on the market mostly come from direct extraction of the plants themselves. This method is problematic, because it is highly energy consuming, costly, and only low yields of rare cannabinoids are achieved, limiting bioactivity characterization and clinical use of those compounds as therapeutic agents. An alternative approach for their production is to engineer microbial hosts, such as yeast, to produce them. This offers a low-cost method to produce our compound of interest, ?9-THCV, with high yield. To do this, we will reconstruct pathways known in C. sativa to produce ?9-THCV in yeast and modulate fluxes of native yeast metabolic pathways to redirect metabolic flux towards the engineered ?9-THCV biosynthetic pathway. My proposed approach aims at optimizing the yield of ?9-THCV using artificial intelligence to modify an enzyme important in the process of ?9-THCV production in silico and test it experimentally. This enzyme also needed to produce other rare cannabinoids, this project will enable development of new cannabinoid-based therapies at low cost with strong benefits for the health and wellbeing of worldwide patients and economic impact on the pharmaceutical sector.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Grimard, Zachary
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~